Abstract

Metastatic carcinoma of presumed renal origin (rCUP) has recently emerged as a new entity within the heterogeneous entity of Cancers of Unknown Primary (CUP) but their biological features and optimal therapeutic management remain unknown. We report the molecular characteristics and clinical outcome of a series of 25 rCUP prospectively identified within the French National Multidisciplinary Tumor Board for CUP. This cohort strongly suggests that rCUP share similarities with common RCC subtypes and benefit from renal-tailored systemic treatment. This study highlights the importance of integrating clinical and molecular data for optimal diagnosis and management of CUP.

Details

Title
Metastatic renal cell carcinoma with occult primary: a multicenter prospective cohort
Author
Jacquin, Nicolas 1   VIAFID ORCID Logo  ; Flippot, Ronan 2 ; Masliah-Planchon, Julien 3 ; Grisay, Guillaume 2 ; Brillet, Riwan 4 ; Dupain, Célia 5 ; Kamal, Maud 5   VIAFID ORCID Logo  ; Guillou, Isabelle 5 ; Gruel, Nadège 6   VIAFID ORCID Logo  ; Servant, Nicolas 7   VIAFID ORCID Logo  ; Gestraud, Pierre 7   VIAFID ORCID Logo  ; Wong, Jennifer 3 ; Cockenpot, Vincent 8   VIAFID ORCID Logo  ; Goncalves, Andreia 8 ; Selves, Janick 9 ; Blons, Hélène 10   VIAFID ORCID Logo  ; Rouleau, Etienne 11 ; Delattre, Olivier 12 ; Gervais, Claire 13 ; Le Tourneau, Christophe 14   VIAFID ORCID Logo  ; Bièche, Ivan 15 ; Allory, Yves 16   VIAFID ORCID Logo  ; Albigès, Laurence 2 ; Watson, Sarah 17   VIAFID ORCID Logo 

1  Institut Curie Research Center, INSERM U830, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Paris, France (GRID:grid.440907.e) (ISNI:0000 0004 1784 3645); Institut Godinot, Department of Medical Oncology, Reims, France (GRID:grid.440907.e) 
2  Université Paris-Saclay, Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535) 
3  Institut Curie Hospital, Somatic Genetic Unit, Department of Genetics, Paris, France (GRID:grid.418596.7) (ISNI:0000 0004 0639 6384) 
4  Institut Curie Hospital, Clinical Bioinformatic Unit, Department of Diagnostic and Theragnostic Medicine, Paris, France (GRID:grid.418596.7) (ISNI:0000 0004 0639 6384) 
5  Institut Curie, Department of Drug Development and Innovation (D3i), Paris, France (GRID:grid.418596.7) (ISNI:0000 0004 0639 6384) 
6  Institut Curie Research Center, INSERM U830, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Paris, France (GRID:grid.440907.e) (ISNI:0000 0004 1784 3645); Institut Curie Hospital, Department of Translational Research, Paris, France (GRID:grid.418596.7) (ISNI:0000 0004 0639 6384) 
7  Mines ParisTech, INSERM U900, CBIO-Centre for Computational Biology, Institut Curie Research Center, Paris, France (GRID:grid.58140.38) (ISNI:0000 0001 2097 6957) 
8  Institut Curie Hospital, Department of Pathology, Paris, France (GRID:grid.418596.7) (ISNI:0000 0004 0639 6384) 
9  University Hospital of Toulouse (IUCT), Department of Pathology, Toulouse, France (GRID:grid.411175.7) (ISNI:0000 0001 1457 2980) 
10  APHP, Department of Biochemistry, Pharmacogenetics and Molecular Oncology, Georges Pompidou European Hospital, Paris, France (GRID:grid.414093.b) (ISNI:0000 0001 2183 5849) 
11  Gustave Roussy Cancer Center, PRISM Center for personalized medicine, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388) 
12  Institut Curie Research Center, INSERM U830, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Paris, France (GRID:grid.440907.e) (ISNI:0000 0004 1784 3645); Institut Curie Hospital, Somatic Genetic Unit, Department of Genetics, Paris, France (GRID:grid.418596.7) (ISNI:0000 0004 0639 6384) 
13  APHP, Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France (GRID:grid.414093.b) (ISNI:0000 0001 2183 5849) 
14  Institut Curie, Department of Drug Development and Innovation (D3i), Paris, France (GRID:grid.418596.7) (ISNI:0000 0004 0639 6384); Institut Curie, INSERM U900, Saint-Cloud, France (GRID:grid.418596.7) (ISNI:0000 0004 0639 6384); Paris-Saclay University, Paris, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535) 
15  Institut Curie Hospital, INSERM U1016, Université Paris Cité, Department of Genetics, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602) 
16  Institut Curie Hospital, Department of Pathology, Saint-Cloud, France (GRID:grid.418596.7) (ISNI:0000 0004 0639 6384); Université Paris-Saclay, Université Versailles St-Quentin, Montigny-le-Bretonneux, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535) 
17  Institut Curie Research Center, INSERM U830, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Paris, France (GRID:grid.440907.e) (ISNI:0000 0004 1784 3645); Institut Curie Hospital, Department of Medical Oncology, Paris, France (GRID:grid.418596.7) (ISNI:0000 0004 0639 6384) 
Pages
147
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
ISSN
2397768X
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41698-024-00648-0
ProQuest document ID
3082446239
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.